Connect with a Spinosad Topical Suspension 0.9% Representative



    Louse crawling

    ParaPRO respects your privacy.

    Indication
    Spinosad Topical Suspension 0.9% is a pediculicide indicated for the topical treatment of head lice infestations in patients six (6) months of age and older.

    Adjunctive Measures
    Spinosad Topical Suspension 0.9% should be used in the context of an overall lice management program:
    • Wash (in hot water) or dry clean all recently worn clothing, hats, used bedding and towels
    • Wash personal care items such as combs, brushes, and hair clips in hot water
    • A fine-toothed comb or special nit comb may be used to remove dead lice and nits.

    Important Safety Information
    Spinosad Topical Suspension 0.9% contains benzyl alcohol and is not recommended for use in neonates and infants below the age of 6 months. Systemic exposure to benzyl alcohol has been associated with serious adverse reactions and death in neonates and low birth-weight infants when administered intravenously. Most common adverse events were: application site redness (3%), eye redness (2%) and application site irritation (1%).

    You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

    SPN-RRW14-000

    Important Safety Information

    Indication
    Spinosad Topical Suspension 0.9% is a pediculicide indicated for the topical treatment of head lice infestations in patients six (6) months of age and older.

    Adjunctive Measures
    Spinosad Topical Suspension 0.9% should be used in the context of an overall lice management program:
    • Wash (in hot water) or dry clean all recently worn clothing, hats, used bedding and towels
    • Wash personal care items such as combs, brushes, and hair clips in hot water
    • A fine-toothed comb or special nit comb may be used to remove dead lice and nits.

    Important Safety Information
    Spinosad Topical Suspension 0.9% contains benzyl alcohol and is not recommended for use in neonates and infants below the age of 6 months. Systemic exposure to benzyl alcohol has been associated with serious adverse reactions and death in neonates and low birth-weight infants when administered intravenously. Most common adverse events were: application site redness (3%), eye redness (2%) and application site irritation (1%).

    You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.